PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg

Detalles Bibliográficos
Autores principales: Kingsbury, D, Quartier, P, Arora, V, Kalabic, J, Kupper, H, Mozaffarian, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045695/
http://dx.doi.org/10.1186/1546-0096-11-S2-P173
_version_ 1782319361240858624
author Kingsbury, D
Quartier, P
Arora, V
Kalabic, J
Kupper, H
Mozaffarian, N
author_facet Kingsbury, D
Quartier, P
Arora, V
Kalabic, J
Kupper, H
Mozaffarian, N
author_sort Kingsbury, D
collection PubMed
description
format Online
Article
Text
id pubmed-4045695
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40456952014-06-20 PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg Kingsbury, D Quartier, P Arora, V Kalabic, J Kupper, H Mozaffarian, N Pediatr Rheumatol Online J Poster Presentation BioMed Central 2013-12-05 /pmc/articles/PMC4045695/ http://dx.doi.org/10.1186/1546-0096-11-S2-P173 Text en Copyright © 2013 Kingsbury et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Kingsbury, D
Quartier, P
Arora, V
Kalabic, J
Kupper, H
Mozaffarian, N
PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
title PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
title_full PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
title_fullStr PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
title_full_unstemmed PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
title_short PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
title_sort pres-final-2161: safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045695/
http://dx.doi.org/10.1186/1546-0096-11-S2-P173
work_keys_str_mv AT kingsburyd presfinal2161safetyandeffectivenessofadalimumabinchildrenwithpolyarticularjuvenileidiopathicarthritisaged2to4yearsor4yearsweighing15kg
AT quartierp presfinal2161safetyandeffectivenessofadalimumabinchildrenwithpolyarticularjuvenileidiopathicarthritisaged2to4yearsor4yearsweighing15kg
AT arorav presfinal2161safetyandeffectivenessofadalimumabinchildrenwithpolyarticularjuvenileidiopathicarthritisaged2to4yearsor4yearsweighing15kg
AT kalabicj presfinal2161safetyandeffectivenessofadalimumabinchildrenwithpolyarticularjuvenileidiopathicarthritisaged2to4yearsor4yearsweighing15kg
AT kupperh presfinal2161safetyandeffectivenessofadalimumabinchildrenwithpolyarticularjuvenileidiopathicarthritisaged2to4yearsor4yearsweighing15kg
AT mozaffariann presfinal2161safetyandeffectivenessofadalimumabinchildrenwithpolyarticularjuvenileidiopathicarthritisaged2to4yearsor4yearsweighing15kg

Ejemplares similares